Canada’s leading medical cannabis provider and Australia’s preeminent medical cannabis supplier to bring three new premium strains to Australian patients
EDMONTON, AB, Feb. 22, 2023 /PRNewswire/ – Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, and MedReleaf Australia today announced the launch of CraftPlant, a new medical cannabis brand for patients in the Australian market.
The CraftPlant brand includes three new products available for doctors to prescribe – Greendae, Navana and HiVolt. All three are developed from ultra-premium cultivars and are THC-dominant with high percentages of terpenes. The cultivars were developed by Occo, Aurora’s leading science and genetics business. The new range is produced under strict EU-GMP certified conditions and will be available in 10g containers.
“Through our partnership with MedReleaf Australia, we are proud to continue to lead the way in the Australian market with the addition of new and innovative products for patients,” says Miguel Martin, CEO of Aurora Cannabis. “As we build on our strategic international growth plans, Australia has proven to be a very promising and sustainable cannabis market that we are committed to.”
Aurora currently holds a 10% ownership stake in MedReleaf Australia, a fully licensed, private company. Together, they provide Australian patients with several Aurora-branded products, including dried flower, oils and soft gels.
Russell Harding, CEO of MedReleaf Australia says, “These new products are the result of dedicated hard work by the teams in both Canada and Australia, providing the most unique cannabis cultivars available in the Australian medical market. With CraftPlant, doctors now have 27 MedReleaf products available for their patients, providing a wide range of possible solutions for patients unable to obtain relief from their prior medications or treatment, and produced under the strictest guidelines.”
For further information about CraftPlant, doctors and health care professionals can contact MedReleaf’s clinical support team or visit their website: www.medreleafaustralia.com.au.